REGULATORY, PRESS RELEASE

WED, MAY 15, 2019 08:31 CET

RLS Global AB (publ) Interim Report Q1 2019

RLS Global AB (publ)
Interim Report Q1 2019

JANUARY−MARCH 2019

  •  Net sales amounted to SEK 233 thousand, a revenue growth of 75 percent.
  •  Earnings before interest and taxes (EBIT) amounted to SEK -5,781 thousand (-4,841).
  •  Earnings per share after dilution at SEK -0.09 (-0.08).
  •  Cash flow from operating activities amounted to SEK -5,541 thousand (-5,981).
  •  Liquid assets at the end of the period at SEK 15,615 thousand (37,841).
  •  Equity ratio was 84 percent (90).

NOTABLE EVENTS DURING THE FIRST QUARTER

  •  January 1st – signed contract with Unident, exclusive distributor for PeriSolv and CariSolv on the Nordic market
  •  March 13th-15th – RLS Global is attending IDS together with Straumann and participate during the launch of “Next Generation Dentistry”

IMPORTANT EVENTS AFTER THE PERIOD

  •  April 10th – ChloraSolv was CE approved
  •  April 17th – the Company was granted a bank credit in order to secure the financing one year ahead.
  •  May – a product specialist for Wound Care is signed and will join in August

TRADING PLACE AND CERTIFIED ADVISOR

RLS Global’s shares have been listed on the Nasdaq First North since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Erik Penser Bank, telephone +46 (0) 8 463 83 00, Email: certifiedadviser@penser.se. During the period 2012 – 2017, the company was listed on Aktietorget.

For more information, please contact:
Karin Fischer, CEO RLS Global AB,
+46 (0) 702 48 46 51, karin.fischer@rlsglobal.se

Eva Jagenheim, CFO RLS Global AB,
+46 (0)76 133 27 47, eva.jagenheim@rlsglobal.se

PUBLICATION
This information is such information that RLS Global AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above contact person, at 8:30 CET on 15th May, 2019.

Press Release